Scaling up GMP-grade dopaminergic cells for Parkinson's disease.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 38181750.
- Also identified by DOI 10.1016/j.stem.2023.12.005.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Stem cell therapy for Parkinson's disease requires demonstration of safety and efficacy of dopaminergic cells derived from a cell line, consideration of dose, and whether this is deliverable at scale. Park et al. demonstrate these requirements for a new hESC line and that their manufacturing methods allow for its scalability.
Medical subject headings
- Parkinson Disease
- Human Embryonic Stem Cells